Pattern of drug therapy related problems encountered by clinical pharmacists in a critical care setting in Nepal Drug therapy related problems in intensive care unit of Nepal

Main Article Content

Upasana Acharya https://orcid.org/0000-0002-0475-661X
P Ravi Shankar https://orcid.org/0000-0001-6105-5636
Subish Palaian https://orcid.org/0000-0002-9323-3940
Resha Dangol https://orcid.org/0000-0001-9871-2353
Nisha Jha https://orcid.org/0000-0003-1089-6042
Anand Thakur https://orcid.org/0000-0003-2192-159X

Keywords

drug therapy, problems, intensive care unit, Nepal

Abstract

Background


Most hospitalized patients experience drug therapy-related problems (DTRPs) resulting in morbidity, mortality, and an increase in the cost of treatment. DTRPs are an important issue and a serious yet preventable problem.


Objective


The study was conducted with the objective to identify DTRPs in the department of critical care medicine of a tertiary care center in Nepal.


Methods


This was a cross-sectional study carried out at the department of critical care medicine in a tertiary care hospital in Kathmandu, Nepal from August to November 2021. All the patients admitted to ICU/ high care unit (HCU) for more than 48 hours during the study period were recruited in this study. Two clinical pharmacists visited the ICU/ HCU daily to identify any drug therapy-related problems. The Pharmaceutical Care Network Europe (PCNE) Classification system version 9.1 was referred for the classification of identified DTRPs. Descriptive statistics were applied for demographic variables. The Chi-square test was used for categorical variables. Pearson correlation was used to study the relationship between patient variables and the number and types of DTRPs. 


Results


DTRPs were identified in 74.2% (n=89) of patients. More than one DTRP was identified in 38.5%. The identified DTRPs were primarily classified into two sections: Problem and Causes., A total of 106 problems were identified among which unnecessary drug treatment (40.5%, n=43) was the most common problem. A total of 137 causes was identified among which drug selection accounted for 44.5% of total causes followed by dose selection (16.8%). The average DTRP per patient was 1.5± 0.7. Antibiotics 30 (22%) and multivitamins, 10 (7%) were the maximal involved in DTRPs. More DTRPs were observed in male patients (n=60,80%). The association between dose selection and gender was significant. Drug selection issues were more observed in patients prescribed multiple drugs and with a shorter hospital stay.


Conclusion


Most DTRPs identified in the study are easily preventable ones. More focus is needed on antibiotic usage in the ICU and special monitoring measures are needed for vulnerable patient groups such as the elderly. Inclusion of more clinical pharmacists can help to identify and mitigate DTRPs. 


Keywords: drug therapy, problems, intensive care unit, Nepal

Abstract 690 | PDF Downloads 576

References

1. Aronson JK. Medication errors: what they are, how they happen, and how to avoid them. QJM: An International Journal of Medicine. 2009;102(8):513-521. https://doi.org/10.1093/qjmed/hcp052
2. Foppe van Mil JW, Horvat N, Westerlund T, et al. Pharmaceutical Care Network Europe Foundation. Classification for Drug related problems. 2020.
3. Van den Bemt PM, Egberts TC, de Jong-van den Berg LT, et al. Drug-related problems in hospitalized patients. Drug Safety. 2000;22(4):321-333. https://doi.org/10.2165/00002018-200022040-00005
4. Blix HS, Viktil KK, Reikvam A, et al. The majority of hospitalized patients have drug-related problems: results from a prospective study in general hospitals. Eur J Clin Pharmacol. 2004;60(9):651-658. https://doi.org/10.1007/s00228-004-0830-4
5. Garin N, Sole N, Lucas B, et al. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci Rep. 2021;11:883. https://doi.org/10.1038/s41598-020-80560-2
6. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001;41:192-199.
7. Mohan G, Selvan L, Eswaran M, et al. Identification of Drug Related Problems by Clinical Pharmacist in Prescriptions with Polypharmacy: A Prospective Interventional Study. Journal of Young Pharmacists. 2018;10(4):460-465. https://doi.org/10.5530/
jyp.2018.10.100
8. Adusumilli PK, Adepu R. Drug related problems: an overview of various classification systems. Asian J Pharm Clin Res. 2014;7:7- 10.
9. Garrouste-Orgeas M, Flaatten H, Moreno R. Understanding medical errors and adverse events in ICU patients. Intensive Care Medicine. 2015;42(1):107-109. https://doi.org/10.1007/s00134-015-3968-x
10. Lee H, Ryu K, Sohn Y, et al. Impact on Patient Outcomes of Pharmacist Participation in Multidisciplinary Critical Care Teams: A Systematic Review and Meta-Analysis. Crit Care Med. 2019;47(9):1243-1250. https://doi.org/10.1097/CCM.0000000000003830
11. Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Medicine. 2003;29(5):691-698. https://doi.org/10.1007/s00134-003-1705-3
12. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282(3):267-270. https://doi.org/10.1001/jama.282.3.267
13. Abunahlah N, Elawaisi A, Velibeyoglu FM, et al. Drug related problems identified by clinical pharmacist at the Internal Medicine Ward in Turkey. Int J Clin Pharm. 2018;40(2):360-367. https://doi.org/10.1007/s11096-017-0585-5
14. Viktil KK, Blix HS. The Impact of Clinical Pharmacists on Drug-Related Problems and Clinical Outcomes. Basic & Clinical Pharmacology & Toxicology. 2008;102(3):275-280. https://doi.org/10.1111/j.1742-7843.2007.00206.x
15. Martins RR, Silva LT, Lopes FM. Impact of medication therapy management on pharmacotherapy safety in an intensive care unit. Int J Clin Pharm. 2019;41:179-188. https://doi.org/10.1007/s11096-018-0763-0
16. Alam K, Palaian S, Anil KA, et al. Pattern of potential medication errors in a tertiary care hospital in Nepal. Indian J Pharm Pract. 2010;3(2):16-22.
17. Alam K, Sharan YK, Ghosh N, et al. Pattern of medication related problems in patients admitted to intensive care units at a Teaching Hospital in Western Nepal: a Pharmacovigilance Study. Pharm Sci Res. 2020;12(10):1282-1287.
18. Karki N, Kandel K, Prasad P. Assessment of Prescription Errors in the Internal Medicine Department of a Tertiary Care Hospital in Nepal: A Cross-Sectional Study. J Lumbini Med Coll. 2021;9(1):1-8.
19. Shrestha R, Prajapati S. Assessment of prescription pattern and prescription error in outpatient Department at Tertiary Care District Hospital, Central Nepal. J Pharm Policy Pract. 2019;12(16). https://doi.org/10.1186/s40545-019-0177-y
20. Shrestha S, Khatiwada AP, Gyawali S, et al. Overview, Challenges and Future Prospects of Drug Information Services in Nepal: A Reflective Commentary. J Multidiscip Healthc. 2020;13:287-295.
https://doi.org/10.2147/JMDH.S238262
21. Shrestha S, Danekhu K, Kc B, et al. Bibliometric analysis of adverse drug reactions and pharmacovigilance research activities in Nepal. Ther Adv Drug Saf. 2020;11. https://doi.org/10.1177/2042098620922480
22. Ghimire R, Prasad P, Parajuli S, et al. Potential Drug-drug Interaction among the Patients Admitted in Intensive Care Units of a Tertiary Care Centre: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2022;60(247):263-267. https://doi.
org/10.31729/jnma.7137 
23. Bhandari B, Lamichhane P, Yadav D, et al. Potential Drug-drug Interactions among Hospital Discharge Prescriptions in a Tertiary Care Centre of Nepal: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc. 2022;60(246):146-150. https://doi.
org/10.31729/jnma.7065 
24. Upreti AR, Shrestha D, Thapa S, et al. Assessment of Potential Drug-Drug Interactions and its Associated Factors in Medical Intensive Care Unit of a Tertiary Care Hospital in Nepal. Nepal Medical College Journal. 2020;22(4):228-232. https://doi.
org/10.3126/nmcj.v22i4.34186 
25. Thapa RK, Joshi I, Thapa P, et al. A Study on Extent of Counseling by Hospital Pharmacists. JAAR. 2017;4(2):99-109. 
26. Shrestha S, Shakya D, Palaian S. Clinical Pharmacy Education and Practice in Nepal: A Glimpse into Present Challenges and Potential Solutions. Adv Med Educ Pract. 2020;11:541-548. https://doi.org/10.2147/AMEP.S257351
27. Tharanon V, Putthipokin K, Sakthong P. Drug-related problems identified during pharmaceutical care interventions in an intensive care unit at a tertiary university hospital. SAGE Open Med. 2022;10:20503121221090881. https://doi.
org/10.1177/20503121221090881 
28. Albayrak A, Başgut B, Bıkmaz GA, et al. Clinical pharmacist assessment of drug-related problems among intensive care unit patients in a Turkish university hospital. BMC Health Serv Res. 2022;22:79. https://doi.org/10.1186/s12913-022-07494-5 
29. Ayhan YE, Karakurt S, Sancar M. The effect of the clinical pharmacist in minimizing drug-related problems and related costs in the intensive care unit in Turkey: A non-randomized controlled study. J Clin Pharm Ther. 2022. https://doi.org/10.1111/
jcpt.13784
30. Shrestha R, Palaian S, Sapkota B, et al. A nationwide exploratory survey assessing perception, practice, and barriers toward pharmaceutical care provision among hospital pharmacists in Nepal. Sci Rep. 2022;12:16590. https://doi.org/10.1038/s41598-
022-16653-x
31. Li XX, Zheng SQ, Gu JH, et al. Drug-Related Problems Identified during Pharmacy Intervention and Consultation: Implementation of an Intensive Care Unit Pharmaceutical Care Model. Front Pharmacol. 2020;11. https://doi.org/10.3389/fphar.2020.571906/
full
32. Nepal G, Bhatta S. Self-medication with Antibiotics in WHO Southeast Asian Region: A Systematic Review. Cureus. 2018;10(4):e2428. https://doi.org/10.7759/cureus
33. Rijal KR, Banjara MR, Dhungel B, et al. Use of antimicrobials and antimicrobial resistance in Nepal: a nationwide survey. Sci Rep. 2021;11(1):11554. https://doi.org/10.1038/s41598-021-90812-4
34. Nepal A, Hendrie D, Robinson S, et al. Analysis of patterns of antibiotic prescribing in public health facilities in Nepal. J Infect Dev Ctries. 2020;14(1):18-27. https://doi.org/10.3855/jidc.11817
35. Basnyat B, Pokharel P, Dixit S, et al. Antibiotic Use, Its Resistance in Nepal and Recommendations for Action: A Situation Analysis. J Nepal Health Res Counc. 2015;13(30):102-111.
36. Möller V, Östholm-Balkhed Å, Berild D, et al. Antibiotic resistance among major pathogens compared to hospital treatment guidelines and antibiotic use in Nordic hospitals 2010-2018. Infect Dis (Lond). 2021;53(8):607-618. https://doi.org/10.1080/2
3744235.2021.1910338
37. Veličković-Radovanović R, Stefanović N, Damnjanović I, et al. Monitoring of antibiotic consumption and development of resistance by enterobacteria in a tertiary care hospital. J Clin Pharm Ther. 2015;40(4):426-430. https://doi.org/10.1111/
jcpt.12283
38. Mascarello M, Simonetti O, Knezevich A, et al. Correlation between antibiotic consumption and resistance of bloodstream bacteria in a University Hospital in North Eastern Italy, 2008-2014. Infection. 2017;45(4):459-467. https://doi.org/10.1007/
s15010-017-0998-z
39. Versporten A, Zarb P, Caniaux I, et al. Global-PPS network. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health. 2018;6(6):e619-e629. https://
doi.org/10.1016/S2214-109X(18)30186-4
40. MacTavish P, Quasim T, Purdie C, et al. Medication-related Problems in Intensive Care Unit Survivors: Learning from a Multicenter Program. Ann Am Thorac Soc. 2020;17(10):1326-1329. https://doi.org/10.1513/AnnalsATS.202005-444

Most read articles by the same author(s)

1 2 > >>